OTraces Inc.

OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite communications ” that is being applied to biological cancer testing for the first time. The result has been cancer blood tests with extraordinary accuracy and precision. OTraces is the only this method can access the diagnostic content of the TME (tumor microenvironment), and that can determine tumor progression non-invasively and in real time. OTraces can boost predictive power and optimize biomarker performance of any correlative diagnostic test ” DNA- and RNA-based approaches included. This technology can detect cancer as early as Stage 0-1 tumors“ at low cost while using ordinary instrumentation deployed in labs and clinics worldwide.